Australia's Clarity Pharmaceuticals extends gains post Jefferies upgrade
19/12/2025 04:26
** Clarity Pharmaceuticals CU6.AX rises 1.4% to A$3.315; set for third straight session of gains ** Stock has gained 13.5% since Wednesday after Jefferies upgraded to "buy" from "hold" ** Brokerage said Phase 2 trial data shows clinical-stage radiopharmaceutical's 64Cu-Sartate in patients with neuroendocrine tumours identified more lesions than competition ** YTD, CU6 down 20.5% (Reporting by Shruti Agarwal in Bengaluru) ((Shruti.Agarwal@thomsonreuters.com))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial